Q2 EPS Estimates for Purple Biotech Raised by HC Wainwright

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Purple Biotech in a report released on Monday, May 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.98) per share for the quarter, up from their prior estimate of ($4.00). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Purple Biotech’s current full-year earnings is ($16.50) per share. HC Wainwright also issued estimates for Purple Biotech’s Q3 2026 earnings at ($1.73) EPS, Q4 2026 earnings at ($2.51) EPS, FY2026 earnings at ($5.31) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.15) EPS, FY2029 earnings at $0.07 EPS and FY2030 earnings at ($0.29) EPS.

A number of other analysts have also recently commented on PPBT. Zacks Research upgraded shares of Purple Biotech from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Weiss Ratings cut shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, May 4th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Purple Biotech has an average rating of “Hold” and a consensus target price of $30.00.

Purple Biotech Trading Down 7.1%

Shares of PPBT stock opened at $3.51 on Wednesday. Purple Biotech has a 12 month low of $3.47 and a 12 month high of $29.00. The stock has a market cap of $4.49 million, a PE ratio of -0.19 and a beta of 0.68. The company’s fifty day moving average price is $4.14 and its 200-day moving average price is $5.88.

Purple Biotech (NASDAQ:PPBT) last announced its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.29.

Hedge Funds Weigh In On Purple Biotech

A hedge fund recently bought a new stake in Purple Biotech stock. Virtu Financial LLC purchased a new position in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 48,993 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned about 0.38% of Purple Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.64% of the company’s stock.

Key Stories Impacting Purple Biotech

Here are the key news stories impacting Purple Biotech this week:

• Positive Sentiment: HC Wainwright lifted its FY2026 earnings estimate for Purple Biotech to ($5.31) per share from a prior forecast of ($16.50), implying a much smaller loss than expected. Purple Biotech analyst update
• Positive Sentiment: The firm also raised its Q2 2026, Q3 2026, and Q4 2026 EPS estimates, suggesting improving expectations across the near-term pipeline outlook. Purple Biotech analyst update
• Positive Sentiment: HC Wainwright increased longer-term estimates for FY2027, FY2028, FY2029, and FY2030, including a move to positive EPS in FY2029, which may signal growing confidence in the company’s future earnings trajectory. Purple Biotech analyst update
• Neutral Sentiment: HC Wainwright reiterated its Buy rating and $30 price target, reinforcing a bullish stance but not adding new operational news. Purple Biotech analyst update
• Neutral Sentiment: The stock recently traded near its 12-month low, so recent analyst optimism may be offset by broader weakness and the company’s very small market cap. Purple Biotech stock overview

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.